Nippon Shinyaku Co., Ltd. (4516.T)
Tokyo · JPY · Healthcare · Drug Manufacturers - Specialty & Generic
¥3,395 (-0.70%) as of
Key statistics
- Market cap
- 228.83B
- P/E (TTM)
- 7.27
- Forward P/E
- 8.27
- EPS (TTM)
- 466.69
- Dividend yield
- 3.61%
- 52-week range
- 3,203.00 – 6,529.00
- Revenue (TTM)
- 180.29B
- Profit margin
- 17.51%
- Analyst target
- ¥3,406.25
- Volume
- 104.40k
About Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc. to develop ATSN-101 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leber congenital amaurosis; and Regenex Bio Inc. to develop RGX-121 and RGX-111 for the treatment of mucopolysaccharidosis type I and II. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Kyoto, Japan
- Employees
- 2,309
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.